ELTX: ELI-002 immunotherapy shows strong early results and is advancing to new combination trials in KRAS cancers
The discussion highlighted advances in lymph node-targeted immunotherapy, with ELI-002 showing promising responses in metastatic pancreatic cancer and a strong safety profile. Upcoming trials will combine ELI-002 with RAS inhibitors and checkpoint inhibitors, targeting a large market of KRAS-mutant…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.